

January 23, 2023

To

The Listing Department

**National Stock Exchange of India Limited** 

Exchange Plaza,

Bandra – Kurla Complex

Bandra (East)

<u>Mumbai – 400 051</u>

Stock Code: INDOCO-EQ

То

The Listing Department

**Bombay Stock Exchange Limited** 

Floor 25, P. J. Towers,

Dalal Street,

 $\underline{Mumbai-400\ 001}$ 

**Stock Code**: 532612

Dear Sirs.

## <u>Subject: USFDA inspection at Indoco Remedies Limited's Solid Oral Formulation</u> <u>Facility (Plant 1) at Goa.</u>

We would like to inform you that the United States Food and Drug Administration (USFDA) has conducted GMP inspection of the Solid Oral Formulation Facility (Plant 1) at Goa. The inspection was conducted from 16<sup>th</sup> January, 2023 to 20<sup>th</sup> January 2023.

The USFDA has issued Form 483 with 9 observations, which will be addressed within stipulated time. We believe that this will not have an impact on the supplies and the existing revenues from this facility.

The Company is committed to maintain compliances across all our facilities with cGMP quality standards at all times.

This is for your information and record.

Thanking you,
Yours faithfully,
For Indoco Remedies Limited

Ramanathan Hariharan Company Secretary & Head- Legal